First results of molecular imaging (FDG and FES) in prospective study for selecting second line hormonotherapy in estrogen receptors positive metastatic breast cancer patients

B. Maucherat; A. Leduc-Pennec; N. Fleury; Ludovic Ferrer; E. Bourbouloux; H. Simon; M. Le Thiec; D. Rusu; V. Fleury; M. Colombie; A. Morel; Françoise Kraeber-Bodéré; Loïc Campion; Caroline Rousseau

Journal articles

First results of molecular imaging (FDG and FES) in prospective study for selecting second line hormonotherapy in estrogen receptors positive metastatic breast cancer patients

B. Maucherat ¹ A. Leduc-Pennec ² N. Fleury ³ Ludovic Ferrer ^{4, 5} E. Bourbouloux ⁶ H. Simon ⁷ M. Le Thiec ¹ D. Rusu ¹ V. Fleury ¹ M. Colombie ¹ A. Morel ¹ Françoise Kraeber-Bodéré ^{4, 1} Loïc Campion ^{8, 9} Caroline Rousseau ^{4, 1}

1 Service de médecine nucléaire [Saint-Herblain]

2 Service de médecine nucléaire [Brest]

3 Délégation à la recherche clinique [CHU Nantes]

4 CRCINA-ÉQUIPE 13 - Nuclear Oncology

CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers

5 Département de Physique [Saint Herblain]

6 Département d'Oncologie [Saint Herblain]

7 Département de Radio-Oncologie [CHRU Brest]

8 CRCINA-ÉQUIPE 11 - Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression

CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers

9 Unité de Biométrie [ICO, Saint Herblain]

Abstract : Aim/Introduction: About 70% of primitive breast cancers had positive estrogen receptors (ER) and may benefit from hormonotherapy. However, ER expression in breast cancer metastases is heterogeneous and about 15% of metastases lost this expression over time. Biopsies were not possible systematically. 16α-18Fluoro-17β-Oestradiol (18FES) is a radiopharmaceutical which predict the response to the first line hormonotherapy. The aim of this prospective study (NCT03442504) was to determine the predictive value of PET at the patient level, before a second line hormonotherapy (2nd- HT) on the FDG response obtained at 6 weeks of treatment. Materials and Methods: We prospectively included 12 ER+ metastatic breast cancer patients, HER2 negative, in progression despite first line hormonotherapy. For the complete study, 60 patients will be included. Due to 2nd-HT proposed by oncologist, we performed 18FES PET-CT (18FES-BL) and 18FDG PET-CT (18FDG-BL) at baseline in the month before the new treatment introduction. Follow-up with 18FDG PET-CT and CT

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Cancer

Complete list of metadata

https://www.hal.inserm.fr/inserm-02337440
Contributor : Elizabeth Bernardo <>
Submitted on : Tuesday, October 29, 2019 - 2:28:28 PM
Last modification on : Sunday, October 25, 2020 - 7:06:29 AM
Long-term archiving on: : Thursday, January 30, 2020 - 8:07:26 PM

First results of molecular imaging (FDG and FES) in prospective study for selecting second line hormonotherapy in estrogen receptors positive metastatic breast cancer patients

File

Identifiers

Collections

Citation

Export

Metrics

75

34

First results of molecular imaging (FDG and FES) in prospective study for selecting second line hormonotherapy in estrogen receptors positive metastatic breast cancer patients

File

Identifiers

Collections

Citation

Export

Share

Metrics

75

34